Polaryx Therapeutics, Inc. Common Stock (PLYX) Stock Price
PLYXStock
$1.99
Market Cap$99.19M
P/E—
PEG Ratio—
Div yield—
Beta-1.41
PLYX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-46.54%
Price vs S&P 500 (4W)-9.08%
VGM Score11.97
PLYX Earnings Surprise History
Q4 25-0.16est. -0.02
Q1 26-0.05est. -0.02
Q2 26-0.03est. -0.04
PLYX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.11
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PLYXPolaryx Therapeutics, Inc. Common Stock | — | — | F | $1.99 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics is a clinical-stage biotech company developing oral small molecule therapies for rare pediatric lysosomal storage diseases (LSDs). Its pipeline includes PLX-200, PLX-300, and PLX-100, designed to address the underlying pathophysiology of these genetic disorders. The company focuses on disease-modifying treatments that target core mechanisms common to multiple LSDs.